Service Number：ABL028

Antibody fragments such as single domain antibodies (dAbs), antigen-binding fragments (Fab), and single chain variable fragments (scFvs) have unique properties that can make them better suited to certain therapeutic applications than full-sized monoclonal antibodies (mAbs).  In comparison with intact antibodies, fragments are smaller, which can allow them to more effectively reach their targets, and they’re also often easier and less expensive to produce.  It allows their binding to concealed epitopes not accessible to complete antibodies.  The smaller size can help offer lower scattering, thus less contrast in images.  From the perspective of therapeutic applications, a small molecular weight also means fast clearance and efficient penetration.  Some therapeutics also use the fragments as they improve penetration into the tissue.

Presently, there are a number of routes to take in order to artificially synthesize an antibody fragment.  Many functional antigen-binding antibody fragments could be engineered by proteolysis of antibodies (papain digestion, pepsin digestions or other enzymatic approaches), generating Fab, Fv or single domains.

With years of research experience in the field of recombinant antibody construction and expression, Abvigen offers antibody fragment production services, we have various expression systems to meet the production for different types of fragmentation antibodies such as scFv, Fab/Fab?, sdAb/VHH, Fc fusion proteins, and chimeric antibody and so on.  Besides, we can offer antibody proteolysis service to engineering antibodies.

Large scale production

High antibody sensitivity

Diverse fragment formats

Various species options

Different expression systems

Retaining the original specificity